Zentalis shares surge 10.56% after-hours after announcing management participation in Guggenheim Biotech Summit.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) surged 10.56% in after-hours trading following its announcement to participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th. The event, featuring management presentations, highlights the company’s progress in developing azenosertib, a first-in-class WEE1 inhibitor for ovarian cancer. As a clinical oncology innovator focused on biomarker-driven therapies, Zentalis emphasized its strategy to advance azenosertib through monotherapy and combination studies, aiming to provide a non-chemo, orally available treatment option. The after-hours rally reflects investor optimism about the company’s visibility at the summit and its pipeline’s potential to address unmet needs in oncology, with the presentation likely to reinforce confidence in its biomarker-driven approach and future clinical milestones.